12-Dec-2025
Pacific Biosciences (PACB) Gets a Hold from Barclays
TipRanks (Mon, 15-Dec 4:26 AM ET)
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Fri, 28-Nov 9:05 AM ET)
PacBio to Present at Upcoming Investor Conferences
Globe Newswire (Thu, 13-Nov 4:05 PM ET)
PacBio Announces Third Quarter 2025 Financial Results
Globe Newswire (Wed, 5-Nov 4:02 PM ET)
Globe Newswire (Wed, 5-Nov 9:05 AM ET)
Globe Newswire (Tue, 4-Nov 9:05 AM ET)
PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025
Globe Newswire (Wed, 22-Oct 4:05 PM ET)
Globe Newswire (Tue, 14-Oct 6:05 AM ET)
PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project
Globe Newswire (Mon, 13-Oct 9:05 AM ET)
Globe Newswire (Wed, 8-Oct 9:05 AM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of December 12, 2025, PACB stock price declined to $2.12 with 4,528,155 million shares trading.
PACB has a beta of 0.89, meaning it tends to be less sensitive to market movements. PACB has a correlation of 0.03 to the broad based SPY ETF.
PACB has a market cap of $640.04 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $38 million in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.03.
In the last 3 years, PACB traded as high as $14.55 and as low as $.85.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): ARKK, ARKG, VTI, IWM, VXF.
PACB has underperformed the market in the last year with a price return of +3.7% while the SPY ETF gained +14.0%. However, in the short term, PACB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +81.2% vs +4.0% return in SPY. But in the last 2 weeks, PACB shares have been beat by the market, returning -8.6% compared to an SPY return of -0.2%.
PACB support price is $2.03 and resistance is $2.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB shares will trade within this expected range on the day.